Abstract

Alzheimer’s disease (AD) patients exhibit neuropsychiatric symptoms that extend beyond classical cognitive deficits, suggesting involvement of subcortical areas. Here, we investigated the role of midbrain dopamine (DA) neurons in AD using the amyloid + tau-driven 3xTg-AD mouse model. We found deficits in reward-based operant learning in AD mice, suggesting possible VTA DA neuron dysregulation. Physiological assessment revealed hyperexcitability and disrupted firing in DA neurons caused by reduced activity of small-conductance calcium-activated potassium (SK) channels. RNA sequencing from contents of single patch-clamped DA neurons (Patch-seq) identified up-regulation of the SK channel modulator casein kinase 2 (CK2), which we corroborated by immunohistochemical protein analysis. Pharmacological inhibition of CK2 restored SK channel activity and normal firing patterns in 3xTg-AD mice. These findings identify a mechanism of ion channel dysregulation in VTA DA neurons that could contribute to behavioral abnormalities in AD, paving the way for novel treatment strategies.

Recent studies unexpectedly indicate involvement of ventral tegmental area dopamine neurons in Alzheimer’s disease (AD). Here, the authors identified the enzyme casein kinase 2 as a mechanistic link between abnormal firing activity and AD pathology.

Details

Title
VTA dopamine neurons are hyperexcitable in 3xTg-AD mice due to casein kinase 2-dependent SK channel dysfunction
Author
Blankenship, Harris E. 1   VIAFID ORCID Logo  ; Carter, Kelsey A. 2 ; Pham, Kevin D. 3 ; Cassidy, Nina T. 4 ; Markiewicz, Andrea N. 2 ; Thellmann, Michael I. 2   VIAFID ORCID Logo  ; Sharpe, Amanda L. 5   VIAFID ORCID Logo  ; Freeman, Willard M. 6   VIAFID ORCID Logo  ; Beckstead, Michael J. 7   VIAFID ORCID Logo 

 Oklahoma Medical Research Foundation, Aging and Metabolism Research Program, Oklahoma City, USA (GRID:grid.274264.1) (ISNI:0000 0000 8527 6890); University of Oklahoma Health Sciences Center, Department of Physiology, Oklahoma City, USA (GRID:grid.266902.9) (ISNI:0000 0001 2179 3618) 
 Oklahoma Medical Research Foundation, Aging and Metabolism Research Program, Oklahoma City, USA (GRID:grid.274264.1) (ISNI:0000 0000 8527 6890) 
 Oklahoma Medical Research Foundation, Genes and Human Disease Research Program, Oklahoma City, USA (GRID:grid.274264.1) (ISNI:0000 0000 8527 6890) 
 Oklahoma Medical Research Foundation, Aging and Metabolism Research Program, Oklahoma City, USA (GRID:grid.274264.1) (ISNI:0000 0000 8527 6890); Oklahoma Medical Research Foundation, Genes and Human Disease Research Program, Oklahoma City, USA (GRID:grid.274264.1) (ISNI:0000 0000 8527 6890) 
 University of Oklahoma Health Sciences Center, Department of Pharmaceutical Sciences, Oklahoma City, USA (GRID:grid.266902.9) (ISNI:0000 0001 2179 3618) 
 Oklahoma Medical Research Foundation, Genes and Human Disease Research Program, Oklahoma City, USA (GRID:grid.274264.1) (ISNI:0000 0000 8527 6890); Oklahoma City Veterans Affairs Medical Center, Oklahoma City, USA (GRID:grid.413864.c) (ISNI:0000 0004 0420 2582) 
 Oklahoma Medical Research Foundation, Aging and Metabolism Research Program, Oklahoma City, USA (GRID:grid.274264.1) (ISNI:0000 0000 8527 6890); University of Oklahoma Health Sciences Center, Department of Physiology, Oklahoma City, USA (GRID:grid.266902.9) (ISNI:0000 0001 2179 3618); Oklahoma City Veterans Affairs Medical Center, Oklahoma City, USA (GRID:grid.413864.c) (ISNI:0000 0004 0420 2582) 
Pages
9673
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3126245674
Copyright
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.